ESTRADERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRADERM (ESTRADERM).
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to transcriptional regulation of genes involved in reproductive, cardiovascular, skeletal, and central nervous system functions. It also has non-genomic effects via membrane-associated receptors.
| Metabolism | Primarily hepatic via CYP3A4-mediated oxidation. Undergoes enterohepatic recirculation. Metabolites include estrone, estriol, and conjugated estrogens (glucuronides and sulfates). |
| Excretion | Estradiol is primarily excreted in urine as glucuronide and sulfate conjugates (estrone, estriol, and their conjugates). Approximately 50-80% of a dose appears in urine, with 10-20% in feces via biliary elimination. |
| Half-life | The terminal elimination half-life of estradiol is approximately 1-2 hours for the parent drug. However, its active metabolite, estrone, has a longer half-life of about 12-24 hours, contributing to sustained clinical effects. |
| Protein binding | Estradiol is approximately 98-99% bound to plasma proteins, primarily sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | The volume of distribution is approximately 1.2 L/kg, indicating extensive distribution into tissues. For a 70 kg individual, Vd is ~84 L. |
| Bioavailability | Transdermal: Approximately 10-20% of the applied dose enters systemic circulation, avoiding first-pass metabolism. Oral bioavailability is <5% due to extensive hepatic first-pass effect. |
| Onset of Action | Transdermal: Therapeutic effects (e.g., relief of menopausal symptoms) are typically observed within 1-4 weeks of continuous use; maximal effects may take 2-3 months. |
| Duration of Action | Transdermal: Continuous application (e.g., twice-weekly patch changes) maintains steady serum levels; clinical effects persist with regular use. Steady-state is reached after 2-4 applications. |
Apply one transdermal patch delivering 0.05 mg estradiol per day twice weekly (every 3-4 days). Dose may be adjusted based on clinical response.
| Dosage form | SYSTEM |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; data insufficient for severe renal impairment. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; no specific dose adjustment recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; not recommended for use in children. |
| Geriatric use | Initiate at lowest effective dose (0.025 mg/day) due to increased risk of adverse effects such as thromboembolism and malignancy; monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTRADERM (ESTRADERM).
| Breastfeeding | Estradiol is excreted in breast milk in low concentrations. M/P ratio is approximately 0.5. May reduce milk production and composition. Use while breastfeeding is generally not recommended, but if necessary, use lowest effective dose for shortest duration. Monitor infant for gynecomastia and other estrogenic effects. |
| Teratogenic Risk | FDA Pregnancy Category X. Estrogen use is contraindicated in pregnancy due to known risk of urogenital abnormalities in female fetuses and possible carcinogenic effects. First trimester exposure increases risk of vaginal adenosis and clear cell adenocarcinoma. Second and third trimester use associated with increased risk of congenital anomalies, including cardiac defects and limb reduction. Estrogens should not be used during pregnancy. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50-79 years of age) receiving oral conjugated estrogens (0.625 mg/day) alone or in combination with medroxyprogesterone acetate relative to placebo. The Women's Health Initiative Memory Study (WHIMS) reported an increased risk of probable dementia in postmenopausal women 65 years of age or older receiving oral conjugated estrogens with or without medroxyprogesterone acetate. An increased risk of endometrial cancer has been reported with unopposed estrogen use in women with a uterus. Estrogens should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known or suspected breast cancer (except in selected metastatic cases)","Known or suspected estrogen-dependent neoplasia","Active or history of venous thromboembolism (deep vein thrombosis, pulmonary embolism)","Active or recent arterial thromboembolic disease (e.g., stroke, MI)","Known protein C, protein S, antithrombin deficiency, or other thrombophilic disorders","Hepatic impairment or disease (e.g., acute hepatitis, decompensated cirrhosis, primary biliary cholangitis)","Known hypersensitivity to estradiol or any component of the formulation","Pregnancy"]
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, weight, and signs of thromboembolism. Assess fetal growth and development if inadvertent exposure occurs. In cases of accidental use during pregnancy, perform ultrasound to evaluate for fetal anomalies. |
| Fertility Effects | Estradiol may inhibit ovulation by suppressing gonadotropin release, thereby reducing fertility. Use for contraception is intended; however, upon discontinuation, fertility usually returns. In assisted reproduction, estradiol is used to support endometrial growth. |
| Precautions |
| ["Thromboembolic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., stroke, MI). Discontinue if VTE occurs.","Cardiovascular disease: Increased risk of stroke and DVT in postmenopausal women; do not use for coronary heart disease prevention.","Malignancy: Unopposed estrogen increases risk of endometrial cancer; addition of progestin mitigates risk. Increased risk of breast cancer, especially with combined therapy.","Dementia: Increased risk of probable dementia in women ≥65 years (WHIMS study).","Gallbladder disease: Increased risk requiring surgery.","Hypertriglyceridemia: Consider discontinuation if pancreatitis occurs.","Fluid retention: Monitor patients with conditions affected by edema (e.g., cardiac/renal impairment).","Hypocalcemia: Use caution in patients with hypoparathyroidism.","Endometriosis: May exacerbate disease.","Hepatic impairment: Contraindicated in acute or chronic liver disease.","Ocular abnormalities: Discontinue if sudden vision loss or papilledema occurs.","Pregnancy: Not indicated; estrogens cause fetal harm.","Lactation: Use with caution; excreted in breast milk."] |